employer cover photo
employer logo
employer logo

Duke Clinical Research Institute

Is this your company?

From authoring THE textbook on clinical research, to becoming an MBA case study. Look elsewhere for your next job. - Management Duke Clinical Research Institute Employee Review

1.0
25 Jan 2020
Recommend
CEO approval
Business outlook

Pros

Duke’s 403-b employer retirement contributions are attractive. The ability to work with Duke faculty on leading edge science can be very rewarding.

Cons

#1. DCRI's rainmakers have left the building. The key faculty members who attracted profitable industry-sponsored research a decade ago are no longer with the DCRI. Without a significant mix of high-margin commercial research projects, the DCRI’s business model is not sustainable – more layoffs are inevitable. #2. Minimal investment over the past ten years in modern information technology and automation. Without a war chest to make the necessary improvements, nor an organization willing to change - the DCRI will continue to fall further behind its growing list of competitors. #3. A government heavy revenue stream is unsustainable. When the United States’ federal deficit hawks reawaken, or the current administration’s mission to de-fund spending on science reaches the NIH – the flow of government funds will dry up. Underbidding government work in order to keep the doors open is not a sound business strategy, long-term underbidding is unsustainable. #4. The DCRI naiveté. Statements like: “The DCRI launched a strategic planning effort in response to changes occurring across the clinical research industry.” Other CROs are doing very well financially and have been keeping pace with the changing market, they are hiring, not laying off. #5. The DCRI’s operating model is based on a twenty-year old direct labor pricing model. The world has changed; direct labor is no longer the primary cost driver in the age of digital research. A revenue model based solely on direct labor costs cannot make the necessary investments in technology to be competitive in the digital world - further evidence of an unsustainable business model. #6. The DCRI is a career killer. Don’t accept lower pay to get your foot in the door, you will be stuck in the same position for eternity, getting 2% annual increases for as long as you stick it out. Promotions will be very rare events in a collapsing organization.

avatar
Duke Clinical Research Institute Response
6y
Thank you for sharing your thoughts with us. Understandably, we disagree with your outlook for DCRI’s future, yet we appreciate your passion. As an academic research organization (ARO), we pride ourselves on working in a mission-based institute that is shaped by more than 125 dedicated faculty who develop clinical research based on the chronic diseases they treat each day at our hospital and clinics. The world’s largest commercial pharmaceutical companies and federal health institutes rely on the DCRI as a trusted partner to lead the way—taking the first steps—in how clinical research should be done. We get to work on some of the most forward-thinking and interesting research being conducted today; we have the opportunity to test innovative methods, especially in the areas of real-word evidence and pragmatic approaches. We are especially proud of the work we do on government grants, which is some of the most rewarding work our teams get to lead. It’s in this spirit that we fully understand that an ARO is not for everyone, but it is for those who approach each day with an unwavering belief that we can change patients’ lives, no matter the challenges we face in the day-to-day design and implementation of clinical trials and studies. Finally, we’re not alone. The DCRI is a part of the Duke School of Medicine and Duke’s larger health system. This association provides great benefits and flexibility, as well as a large playing field for finding ways to advance your career. Again thank you for taking time to share your thoughts and we wish you well in your career.

Explore other reviews about Duke Clinical Research Institute

5.0
4 Mar 2026
Recommend
CEO approval
Business outlook

Pros

Very educational, gave me lots of opportunities to develop my skills in a practical way.

Cons

Lots of downtime waiting for results but that's pretty normal for labwork.

3.0
18 May 2026
Recommend
CEO approval
Business outlook

Pros

- Very friendly workplace with genuinely nice people at the contributor level - Good benefits, relaxed environment promotes work/life balance - Almost no way to get fired, other than thru a company-wide RIF

Cons

- Company-wide RIFs can happen due to anything, including general budget cuts, FDA re-alignment, or whatever will spook leadership - Absurd approach to raises and advancement that is frankly insulting to high performers

See reviews by: Helpful|Rating|Date|All